Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Methylnaltrexone for opioid-induced constipation in pediatric oncology patients.

Rodrigues A, Wong C, Mattiussi A, Alexander S, Lau E, Dupuis LL.

Pediatr Blood Cancer. 2013 Oct;60(10):1667-70. doi: 10.1002/pbc.24615. Epub 2013 Jun 14.

PMID:
23766091
2.

Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study.

Michna E, Blonsky ER, Schulman S, Tzanis E, Manley A, Zhang H, Iyer S, Randazzo B.

J Pain. 2011 May;12(5):554-62. doi: 10.1016/j.jpain.2010.11.008. Epub 2011 Mar 22.

PMID:
21429809
3.

Methylnaltrexone for opioid-induced constipation in patients with advanced illness: a 3-month open-label treatment extension study.

Lipman AG, Karver S, Cooney GA, Stambler N, Israel RJ.

J Pain Palliat Care Pharmacother. 2011;25(2):136-45. doi: 10.3109/15360288.2011.573531.

PMID:
21657861
4.

Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness.

Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C, Israel RJ.

J Pain Symptom Manage. 2009 Nov;38(5):683-90. doi: 10.1016/j.jpainsymman.2009.02.234. Epub 2009 Aug 26.

PMID:
19713070
5.

Methylnaltrexone in treatment of opioid-induced constipation in a pediatric patient.

Lee JM, Mooney J.

Clin J Pain. 2012 May;28(4):338-41. doi: 10.1097/AJP.0b013e31822ad94c.

PMID:
21876436
6.

Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study.

Portenoy RK, Thomas J, Moehl Boatwright ML, Tran D, Galasso FL, Stambler N, Von Gunten CF, Israel RJ.

J Pain Symptom Manage. 2008 May;35(5):458-68. doi: 10.1016/j.jpainsymman.2007.12.005.

PMID:
18440447
7.

Methylnaltrexone for opioid-induced constipation in advanced illness.

Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, Stambler N, Kremer AB, Israel RJ.

N Engl J Med. 2008 May 29;358(22):2332-43. doi: 10.1056/NEJMoa0707377.

8.

Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery.

Anissian L, Schwartz HW, Vincent K, Vincent HK, Carpenito J, Stambler N, Ramakrishna T.

J Hosp Med. 2012 Feb;7(2):67-72. doi: 10.1002/jhm.943. Epub 2011 Oct 13.

PMID:
21998076
9.

Efficacy and Tolerability of Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: A Responder Analysis of 2 Randomized, Placebo-Controlled Trials.

Nalamachu SR, Pergolizzi J, Taylor R Jr, Slatkin NE, Barrett AC, Yu J, Bortey E, Paterson C, Forbes WP.

Pain Pract. 2015 Jul;15(6):564-71. doi: 10.1111/papr.12218. Epub 2014 May 10.

PMID:
24815199
10.

Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis.

Michna E, Weil AJ, Duerden M, Schulman S, Wang W, Tzanis E, Zhang H, Yu D, Manley A, Randazzo B.

Pain Med. 2011 Aug;12(8):1223-30. doi: 10.1111/j.1526-4637.2011.01189.x. Epub 2011 Aug 2.

11.

Methylnaltrexone: MNTX.

[No authors listed]

Drugs R D. 2006;7(6):374-8. Review.

PMID:
17073520
12.
13.

Methylnaltrexone for opioid-induced constipation in a pediatric oncology patient.

Kissling KT, Mohassel LR, Heintz J.

J Pain Symptom Manage. 2012 Jul;44(1):e1-3. doi: 10.1016/j.jpainsymman.2012.04.001. No abstract available.

PMID:
22770490
14.

Use of methylnaltrexone to induce laxation in acutely injured patients with burns and necrotizing soft-tissue infections.

Hewitt K, Lin H, Faraklas I, Morris S, Cochran A, Saffle J.

J Burn Care Res. 2014 Mar-Apr;35(2):e106-11. doi: 10.1097/BCR.0b013e31829b399d.

PMID:
23877147
15.

Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone.

Gatti A, Sabato AF.

Clin Drug Investig. 2012 May 1;32(5):293-301. doi: 10.2165/11598000-000000000-00000. Review.

PMID:
22413747
16.

Methylnaltrexone for opioid-induced constipation in advanced illness.

Chappell D, Rehm M, Conzen P.

N Engl J Med. 2008 Sep 4;359(10):1071; author reply 1071. No abstract available.

PMID:
18777614
17.

Methylnaltrexone: a novel approach for the management of opioid-induced constipation in patients with advanced illness.

Diego L, Atayee R, Helmons P, von Gunten CF.

Expert Rev Gastroenterol Hepatol. 2009 Oct;3(5):473-85. doi: 10.1586/egh.09.42. Review.

PMID:
19817669
18.

Methylnaltrexone for Opioid-Induced Constipation in Children and Adolescents and Young Adults with Progressive Incurable Cancer at the End of Life.

Flerlage JE, Baker JN.

J Palliat Med. 2015 Jul;18(7):631-3. doi: 10.1089/jpm.2014.0364. Epub 2015 Apr 30.

19.

Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms.

Iyer SS, Randazzo BP, Tzanis EL, Schulman SL, Zhang H, Wang W, Manley AL.

Value Health. 2011 Jan;14(1):177-83. doi: 10.1016/j.jval.2010.11.003.

20.

Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects.

Yuan CS.

J Support Oncol. 2004 Mar-Apr;2(2):111-7; discussion 119-22. Review.

PMID:
15328815
Items per page

Supplemental Content

Write to the Help Desk